Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

Table 3 Effect of tolvaptan 60 mg at baseline, during, and after systemic inhibition of NO synthesis on plasma concentration of sodium and plasma osmolality in a randomized, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

Periods	Baseline	L-NMMA		Post infusion		p (GLM-within)
Periods	0–90 min	90–120 min	120–150 min	150–180 min	180–210 min	p (GLM-within)
p-sodium (mmol/l)
Placebo	139 ± 2	138 ± 2	138 ± 2	138 ± 1	137 ± 2	< 0.0001
Tolvaptan 60 mg	141 ± 2	141 ± 2	141 ± 2	142 ± 2	141 ± 2	< 0.0001
p (GLM between)	< 0.0001
p (aired t-test, between)	0.001	< 0.0001	< 0.0001	< 0.0001	< 0.0001
p- osm (mosm/kg)
Placebo	285 ± 5	283 ± 4	282 ± 5	283 ± 4	281 ± 4	< 0.0001
Tolvaptan 60 mg	288 ± 5	290 ± 5	289 ± 5	290 ± 5	289 ± 5	< 0.0001
p (GLM between)	< 0.0001
p (paired t-test, between)	0.024	< 0.0001	< 0.0001	< 0.0001	< 0.0001

Data are given as mean ± SD. General linear model (GLM) with repeated measurements was used for comparison within and between groups. Post-hoc Bonferoni test was used for comparison of infusion period (90–150 min) vs baseline period (0–90 min) and post infusion period (150–210 min) vs baseline period
Paired t-test was performed for comparison between treatments at baseline period (0–90 min), L-NMMA period (90–150 min) and post-infusion period (150–210 min)

ISSN: 1471-2369